Leveraging Evolving Data to Inform Treatment in HR-Positive, HER2-Negative Advanced Breast Cancer

Download All
Watch the interactive on-demand Webcast and download the slides from a CCO symposium at SABCS 2019 to get up to date on the latest clinical data informing optimal treatment of HR+/HER2- MBC, including expert discussion of patient cases and a look ahead at promising agents in the setting of endocrine therapy–pretreated disease that may soon change practice.
Joyce O'Shaughnessy, MD
Program Director
Hope S. Rugo, MD
Eric P. Winer, MD

On-Demand Webcast

In this CME/MOC-certified, on-demand Webcast of a CCO symposium at SABCS 2019, a panel of experts review and discuss evolving strategies for treating HR-positive, HER2-negative advanced breast cancer.

Joyce O'Shaughnessy, MD
Program Director
Hope S. Rugo, MD Eric P. Winer, MD
Physicians: maximum of 1.75 AMA PRA Category 1 Credits US Physicians: maximum of 1.75 Medical Knowledge MOC point(s) Released: January 21, 2020 Expired: No longer available for credit
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Immunomedics, Inc.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.